Evolus Added to NASDAQ Biotechnology Index
December 19 2018 - 8:01AM
Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic
medicine, today announced that the company has been selected for
addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The
addition will become effective prior to the market open on Monday,
December 24, 2018.
The Nasdaq Biotechnology Index (NBI) is designed
to track the performance of a set of NASDAQ-listed securities that
meet certain eligibility criteria and are classified as either
biotechnology or pharmaceuticals, according to the Industry
Classification Benchmark (ICB). These requirements include minimum
market capitalization and average daily trading volume. The NBI is
ranked annually and forms the basis for a number of Exchange Traded
Funds (ETFs), including the iShares Nasdaq Biotechnology ETF. For
more information about the Nasdaq Biotechnology Index visit
https://indexes.nasdaqomx.com.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic
medicine focused on providing physicians and their patients with
expanded choices in aesthetic treatments and procedures. Evolus’
lead candidate Jeuveau, also known by the chemical name
prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A
complex that was approved by Health Canada for the
temporary improvement in the appearance of moderate to severe
glabellar lines in adult patients under 65 years of age and is
being evaluated for marketing approval in the United
States and other areas.
Investors:Ashwin Agarwal, EvolusTel:
+1-949-284-4559Email: IR@Evolus.com
Brian Johnston, The Ruth GroupTel: +1
646-536-7028Email: IR@Evolus.com
General Media:Kirsten Thomas, The Ruth
GroupTel: +1-508-280-6592Email: kthomas@theruthgroup.com
Trade Media:Dani Shaffer, Alison Brod Marketing
+ CommunicationsTel: +1-212-230-1800Email:
evolus@alisonbrodmc.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Sep 2023 to Sep 2024